サンプル依頼リスト カート
  • English
  • Korean
表紙：大うつ病性障害の世界市場レポート 2024年
市場調査レポート
商品コード
1415789

大うつ病性障害の世界市場レポート 2024年

Major Depressive Disorder Global Market Report 2024
出版日: 受注後更新 | 発行: The Business Research Company | ページ情報: 英文 175 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
大うつ病性障害の世界市場レポート 2024年
出版日: 受注後更新
発行: The Business Research Company
ページ情報: 英文 175 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 目次
概要

大うつ病性障害の市場規模は近年着実に成長しています。2023年の59億6,000万米ドルから2024年には61億2,000万米ドルへとCAGR2.7％で拡大します。実績期間の成長は、医薬品の進歩、メンタルヘルスに対する意識、心理療法、公衆衛生への取り組みに起因しています。

不安の有病率の増加は、大うつ病性障害市場の拡大を促進する構えです。不安はストレスに対する一般的な反応であり、恐怖、恐れ、不安の感情を引き起こします。日常的な出来事に対する一時的、強烈、持続的な不安として現れます。不安は大うつ病性障害に大きな影響を与え、神経過敏、イライラ、睡眠障害、集中力低下などの症状を引き起こします。例えば、2021年4月の米国疾病予防管理センターのデータによると、2020年8月から2021年2月の間に、不安や抑うつ疾患の症状を訴える人の割合は36.4％から41.5％に上昇しました。さらに、メンタルヘルスの治療に対するアンメットニーズを示す人の割合は9.2％から11.7％に増加しました。その結果、不安症例の急増が大うつ病性障害市場の成長を促進しています。

2023年の大うつ病性障害市場で最大の地域は北米でした。大うつ病性障害レポートがカバーしている地域は、アジア太平洋、西欧、中東欧、北米、南米、中東・アフリカです。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

  • 高インフレが市場に与える影響
  • ウクライナ・ロシア戦争が市場に与える影響
  • COVID-19による市場への影響

第5章 世界市場規模と成長

  • 世界の大うつ病性障害市場促進要因と抑制要因
    • 市場の促進要因
    • 市場の抑制要因
  • 世界の大うつ病性障害の市場規模実績と成長率、2018年から2023年
  • 世界の大うつ病性障害市場規模と成長予測、2023年～2028年、2033年

第6章 市場セグメンテーション

  • 世界の大うつ病性障害市場、治療別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 心理療法
  • 薬剤
  • 電気けいれん療法（ECT）
  • 経頭蓋磁気刺激（TMS）
  • その他の治療法
  • 世界の大うつ病性障害市場、診断別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 身体検査
  • 臨床検査
  • 精神医学的評価
  • 精神障害の診断と統計マニュアル（DSM-5）
  • その他の診断
  • 世界の大うつ病性障害市場、エンドユーザー別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • クリニック
  • 病院
  • その他のエンドユーザー

第7章 地域および国の分析

  • 世界の大うつ病性障害市場、地域別、実績および予測、2018-2023、2023-2028年、2033年
  • 世界の大うつ病性障害市場、国別、実績および予測、2018-2023、2023-2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • 大うつ病性障害市場の競合情勢
  • 大うつ病性障害市場の企業プロファイル
    • Pfizer Inc.
    • Janssen Research And Development LLC
    • Merck and Co. Inc.
    • Novartis AG
    • Sanofi-Aventis US LLC

第31章 その他の主要および革新的な企業

  • Bristol Myers Squibb Co.
  • AstraZeneca plc
  • GlaxoSmithKline plc
  • Takeda Pharmaceutical Company Limited
  • Eli Lilly and Company
  • Biogen Inc.
  • Otsuka Pharmaceuticals Co.Ltd.
  • Forest Laboratories Inc.
  • H. Lundbeck A/S
  • Richter Gedeon plc
  • Allergan plc
  • Neurocrine Biosciences Inc.
  • BlackThorn Therapeutics Inc.
  • Intra-Cellular Therapies Inc.
  • Axsome Therapeutics Inc.

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の見通しと可能性の分析

第36章 付録

目次
Product Code: r12388

“Major Depressive Disorder Global Market Report 2024 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on major depressive disorder market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for major depressive disorder? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The major depressive disorder market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

  • 1) By Treatment: Psychotherapy; Medications; Electroconvulsive Therapy (ECT); Transcranial Magnetic Stimulation (TMS); Other Treatments
  • 2) By Diagnosis: Physical Examinations; Laboratory Tests; Psychiatric Evaluations; Diagnostic And Statistical Manual of Mental Disorders (DSM-5); Other Diagnosis
  • 3) By End-User: Clinics; Hospitals; Other End-Users
  • Companies Mentioned: Pfizer Inc.; Janssen Research And Development LLC; Merck and Co. Inc.; Novartis AG; Sanofi-Aventis US LLC
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Major depressive disorder, often referred to as clinical depression, is a mood disorder characterized by persistent feelings of sadness and a loss of interest in daily activities. These symptoms can disrupt essential aspects of life, such as sleep, appetite, and work performance, extending beyond typical mood fluctuations and profoundly affecting a person's thoughts, emotions, behavior, and overall well-being. Managing major depressive disorder involves various medical interventions to promote an individual's emotional health.

The key treatments for major depressive disorder encompass psychotherapy, medications, electroconvulsive therapy (ECT), transcranial magnetic stimulation (TMS), and other therapeutic approaches. Psychotherapy involves the guidance of a trained mental health professional who assists individuals or groups in addressing emotional, psychological, and behavioral challenges. The diagnosis of major depressive disorder can be made through physical examinations, laboratory tests, psychiatric evaluations, references to the Diagnostic and Statistical Manual of Mental Disorders (DSM-5), and other clinical methods. These interventions and evaluations are typically administered in various healthcare settings, including hospitals, clinics, and other medical facilities.

The major depressive disorder market research report is one of a series of new reports from The Business Research Company that provides major depressive disorder market statistics, including major depressive disorder industry global market size, regional shares, competitors with a major depressive disorder market share, detailed major depressive disorder market segments, market trends and opportunities and any further data you may need to thrive in the major depressive disorder industry. This major depressive disorder market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The major depressive disorder market size has grown steadily in recent years. It will grow from $5.96 billion in 2023 to $6.12 billion in 2024 at a compound annual growth rate (CAGR) of 2.7%. The growth in the historic period can be attributed to pharmaceutical advances, mental health awareness, psychological therapies, public health initiatives.

The major depressive disorder market size is expected to see steady growth in the next few years. It will grow to $6.84 billion in 2028 at a compound annual growth rate (CAGR) of 2.8%. The growth in the forecast period can be attributed to precision medicine, telepsychiatry and teletherapy, novel treatment modalities, global expansion of mental health services. Major trends in the forecast period include early intervention, peer support and online communities, holistic approaches, resilience and coping strategies.

The major depressive disorder market is anticipated to witness substantial growth due to the increasing prevalence of substance and alcohol abuse. Substance and alcohol abuse refer to the excessive and harmful consumption of substances, including alcohol, resulting in adverse physical, psychological, and social consequences. These behaviors often co-occur with major depressive disorder, reinforcing each other and heightening the risks of physical and mental harm. As an illustration, in December 2022, data from the Office for National Statistics (ONS), a UK government department, revealed that 2.6% of adults aged 16 to 59 had reported drug use, up from 2.1% in 2020. Additionally, a report from Kirin Holdings Company Limited, a Japanese beverage company, disclosed that global beer consumption reached 185.60 million kiloliters in 2021, marking a 4.0% increase from the previous year. Consequently, the surge in substance and alcohol abuse cases is propelling the major depressive disorder market's growth.

Reduced funding for mental health is impeding the growth of the major depressive disorder market in the forecast period. The reduction in funding may lead to resource constraints for mental health facilities and providers, resulting in longer appointment wait times, decreased access to specialized care, and strained mental health infrastructure. These constraints have a direct impact on the quality of care offered to MDD patients. For instance, in May 2023, findings from PLOS, a US-based non-profit publisher of open access journals, revealed that mental health received less than 1% of the nation's entire health budget. Consequently, the curtailment of mental health funding is obstructing the expansion of the major depressive disorder market.

The increasing prevalence of anxiety is poised to drive the expansion of the major depressive disorder market. Anxiety is a common response to stress that triggers feelings of fear, apprehension, and uneasiness. It manifests as a temporary, intense, and persistent apprehension about everyday occurrences. Anxiety significantly influences major depressive disorder, contributing to symptoms like nervousness, irritability, and difficulties with sleep and concentration. For instance, data from the Centers for Disease Control and Prevention in April 2021 indicated that between August 2020 and February 2021, the percentage of individuals reporting symptoms of anxiety or depressive illnesses rose from 36.4% to 41.5%. Moreover, the proportion of those indicating an unmet need for mental health treatment increased from 9.2% to 11.7%. Consequently, the upsurge in anxiety cases propels the growth of the major depressive disorder market.

Prominent companies within the major depressive disorder market are concentrating on the development of pioneering products and obtaining regulatory approvals to gain a competitive edge. The approval of novel drugs for major depressive disorder treatment, such as VRAYLAR (cariprazine), is on the rise to address the demand for more effective and safer treatments. For instance, in December 2022, the US-based pharmaceutical company AbbVie Inc. received FDA (Food and Drug Administration) approval for VRAYLAR (cariprazine) as an adjunctive therapy alongside antidepressants for the treatment of major depressive disorder (MDD) in adults. VRAYLAR represents an innovative atypical antipsychotic medication that rebalances dopamine and serotonin levels in the brain. It stands as the first atypical antipsychotic to be approved for adjunctive major depressive disorder treatment, offering the convenience of a once-daily capsule.

In March 2022, AbbVie Inc., a US-based biopharmaceutical firm, acquired Syndesi Therapeutics SA for $130 million. This strategic acquisition is intended to bolster AbbVie Inc.'s neuroscience portfolio and expand its research and development capabilities in neuropsychiatric and neurodegenerative disorders. Syndesi Therapeutics SA, a Belgium-based biotechnology company, specializes in the development of therapeutic products for major depressive disorders and other neuropsychiatric conditions.

Major players in the major depressive disorder market are Pfizer Inc., Janssen Research And Development LLC, Merck and Co. Inc., Novartis AG, Sanofi-Aventis US LLC, Bristol Myers Squibb Co., AstraZeneca PLC, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Biogen Inc., Otsuka Pharmaceuticals Co.Ltd., Forest Laboratories Inc., H. Lundbeck A/S, Richter Gedeon PLC, Allergan PLC, Neurocrine Biosciences Inc., BlackThorn Therapeutics Inc., Intra-Cellular Therapies Inc., Axsome Therapeutics Inc., Luye Pharma Group, BioLite Inc., BrainsWay Ltd., Neumora Therapeutics Inc., Chase Therapeutics Corporation, SAGE Therapeutics Inc., Arrivo Bioventures LLC, Relmada Therapeutics Inc., Fabre-Kramer Pharmaceuticals Inc., Vistagen Therapeutics Inc.

North America was the largest region in the major depressive disorder market in 2023. The regions covered in major depressive disorder report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the major depressive disorder market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The major depressive disorder market consists of revenues earned by entities by providing services such as teletherapy, integrated care, cognitive behavioral therapy, interpersonal therapy, mindfulness-based therapy and residential treatment. The market value includes the value of related goods sold by the service provider or included within the service offering. The major depressive disorder market also includes sales of monoamine oxidase inhibitors, tricyclic antidepressants and mirtazapine. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Table of Contents

1. Executive Summary

2. Major Depressive Disorder Market Characteristics

3. Major Depressive Disorder Market Trends And Strategies

4. Major Depressive Disorder Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On The Market
  • 4.2. Ukraine-Russia War Impact On The Market
  • 4.3. COVID-19 Impact On The Market

5. Global Major Depressive Disorder Market Size and Growth

  • 5.1. Global Major Depressive Disorder Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Major Depressive Disorder Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Major Depressive Disorder Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Major Depressive Disorder Market Segmentation

  • 6.1. Global Major Depressive Disorder Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Psychotherapy
  • Medications
  • Electroconvulsive Therapy (ECT)
  • Transcranial Magnetic Stimulation (TMS)
  • Other Treatments
  • 6.2. Global Major Depressive Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Physical Examinations
  • Laboratory Tests
  • Psychiatric Evaluations
  • Diagnostic And Statistical Manual of Mental Disorders (DSM-5)
  • Other Diagnosis
  • 6.3. Global Major Depressive Disorder Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Clinics
  • Hospitals
  • Other End-Users

7. Major Depressive Disorder Market Regional And Country Analysis

  • 7.1. Global Major Depressive Disorder Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Major Depressive Disorder Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Major Depressive Disorder Market

  • 8.1. Asia-Pacific Major Depressive Disorder Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Major Depressive Disorder Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Major Depressive Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.4. Asia-Pacific Major Depressive Disorder Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Major Depressive Disorder Market

  • 9.1. China Major Depressive Disorder Market Overview
  • 9.2. China Major Depressive Disorder Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Major Depressive Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.4. China Major Depressive Disorder Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Major Depressive Disorder Market

  • 10.1. India Major Depressive Disorder Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Major Depressive Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India Major Depressive Disorder Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Major Depressive Disorder Market

  • 11.1. Japan Major Depressive Disorder Market Overview
  • 11.2. Japan Major Depressive Disorder Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Major Depressive Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.4. Japan Major Depressive Disorder Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Major Depressive Disorder Market

  • 12.1. Australia Major Depressive Disorder Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Major Depressive Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia Major Depressive Disorder Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Major Depressive Disorder Market

  • 13.1. Indonesia Major Depressive Disorder Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Major Depressive Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia Major Depressive Disorder Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Major Depressive Disorder Market

  • 14.1. South Korea Major Depressive Disorder Market Overview
  • 14.2. South Korea Major Depressive Disorder Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Major Depressive Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.4. South Korea Major Depressive Disorder Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Major Depressive Disorder Market

  • 15.1. Western Europe Major Depressive Disorder Market Overview
  • 15.2. Western Europe Major Depressive Disorder Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Major Depressive Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.4. Western Europe Major Depressive Disorder Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Major Depressive Disorder Market

  • 16.1. UK Major Depressive Disorder Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Major Depressive Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK Major Depressive Disorder Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Major Depressive Disorder Market

  • 17.1. Germany Major Depressive Disorder Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Major Depressive Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany Major Depressive Disorder Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Major Depressive Disorder Market

  • 18.1. France Major Depressive Disorder Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.2. France Major Depressive Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.3. France Major Depressive Disorder Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Major Depressive Disorder Market

  • 19.1. Italy Major Depressive Disorder Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.2. Italy Major Depressive Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.3. Italy Major Depressive Disorder Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Major Depressive Disorder Market

  • 20.1. Spain Major Depressive Disorder Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.2. Spain Major Depressive Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.3. Spain Major Depressive Disorder Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Major Depressive Disorder Market

  • 21.1. Eastern Europe Major Depressive Disorder Market Overview
  • 21.2. Eastern Europe Major Depressive Disorder Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Major Depressive Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.4. Eastern Europe Major Depressive Disorder Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Major Depressive Disorder Market

  • 22.1. Russia Major Depressive Disorder Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Major Depressive Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia Major Depressive Disorder Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Major Depressive Disorder Market

  • 23.1. North America Major Depressive Disorder Market Overview
  • 23.2. North America Major Depressive Disorder Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Major Depressive Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.4. North America Major Depressive Disorder Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Major Depressive Disorder Market

  • 24.1. USA Major Depressive Disorder Market Overview
  • 24.2. USA Major Depressive Disorder Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Major Depressive Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.4. USA Major Depressive Disorder Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Major Depressive Disorder Market

  • 25.1. Canada Major Depressive Disorder Market Overview
  • 25.2. Canada Major Depressive Disorder Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Major Depressive Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.4. Canada Major Depressive Disorder Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Major Depressive Disorder Market

  • 26.1. South America Major Depressive Disorder Market Overview
  • 26.2. South America Major Depressive Disorder Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Major Depressive Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.4. South America Major Depressive Disorder Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Major Depressive Disorder Market

  • 27.1. Brazil Major Depressive Disorder Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Major Depressive Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil Major Depressive Disorder Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Major Depressive Disorder Market

  • 28.1. Middle East Major Depressive Disorder Market Overview
  • 28.2. Middle East Major Depressive Disorder Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Major Depressive Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.4. Middle East Major Depressive Disorder Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Major Depressive Disorder Market

  • 29.1. Africa Major Depressive Disorder Market Overview
  • 29.2. Africa Major Depressive Disorder Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Major Depressive Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.4. Africa Major Depressive Disorder Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Major Depressive Disorder Market Competitive Landscape And Company Profiles

  • 30.1. Major Depressive Disorder Market Competitive Landscape
  • 30.2. Major Depressive Disorder Market Company Profiles
    • 30.2.1. Pfizer Inc.
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. Janssen Research And Development LLC
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. Merck and Co. Inc.
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. Novartis AG
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. Sanofi-Aventis US LLC
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. Major Depressive Disorder Market Other Major And Innovative Companies

  • 31.1. Bristol Myers Squibb Co.
  • 31.2. AstraZeneca plc
  • 31.3. GlaxoSmithKline plc
  • 31.4. Takeda Pharmaceutical Company Limited
  • 31.5. Eli Lilly and Company
  • 31.6. Biogen Inc.
  • 31.7. Otsuka Pharmaceuticals Co.Ltd.
  • 31.8. Forest Laboratories Inc.
  • 31.9. H. Lundbeck A/S
  • 31.10. Richter Gedeon plc
  • 31.11. Allergan plc
  • 31.12. Neurocrine Biosciences Inc.
  • 31.13. BlackThorn Therapeutics Inc.
  • 31.14. Intra-Cellular Therapies Inc.
  • 31.15. Axsome Therapeutics Inc.

32. Global Major Depressive Disorder Market Competitive Benchmarking

33. Global Major Depressive Disorder Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Major Depressive Disorder Market

35. Major Depressive Disorder Market Future Outlook and Potential Analysis

  • 35.1 Major Depressive Disorder Market In 2028 - Countries Offering Most New Opportunities
  • 35.2 Major Depressive Disorder Market In 2028 - Segments Offering Most New Opportunities
  • 35.3 Major Depressive Disorder Market In 2028 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer